CD44, a cell surface glycoprotein, is involved in lymphocyte trafficking from the blood to lymphatic tissues, and is of importance in dissemination of lymphoma. A variant form of CD44 that has additional amino acids in the common protein backbone (CD44v6) also seems to play a role in the metastatic dissemination of malignancies. We measured serum CD44 and CD44v6 in 34 patients with lymphoma and in healthy controls by dot blot assay. Small amounts of both CD44 (range, 10 to 80 nglmL) and CD44v6 could be detected in sera of all controls. Serum CD44 was elevated in all patients with lymphoma before treatment (range, 70 to >2,000 D44 GLYCOPROTEIN is widely distributed in the body. Leukocytes, erythrocytes, many types of epithelial cells, fibroblasts, smooth muscle cells, and glial cells of the central nervous system express the CD44 molecule.'.* However, the size of CD44 varies in different cell types. Most hematopoietic cells express the standard 90-kD form.' but lymphocytes also have a minor chondroitin sulphate containing 180-kD form. In epithelial cell lines, 140-to 160-kD forms of CD44 are predominant, and even larger forms up to 230 kD have been de~cribed.~,' Different forms of CD44 are created both by alternative splicing and posttranslational CD44 is a multifunctional molecule that mediates adhesion of lymphocytes both to vascular endothelium and to several extracellular matrix proteins.' It is involved in lymphohematopoiesis,9 in homotypic cell adhesion,'" in T-cell activation and adherence," in cytokine release," and lateral movement of cells."
D44 GLYCOPROTEIN is widely distributed in the body. Leukocytes, erythrocytes, many types of epithelial cells, fibroblasts, smooth muscle cells, and glial cells of the central nervous system express the CD44 molecule.'.* However, the size of CD44 varies in different cell types. Most hematopoietic cells express the standard 90-kD form.' but lymphocytes also have a minor chondroitin sulphate containing 180-kD form. In epithelial cell lines, 140-to 160-kD forms of CD44 are predominant, and even larger forms up to 230 kD have been de~cribed.~,' Different forms of CD44 are created both by alternative splicing and posttranslational CD44 is a multifunctional molecule that mediates adhesion of lymphocytes both to vascular endothelium and to several extracellular matrix proteins.' It is involved in lymphohematopoiesis,9 in homotypic cell adhesion,'" in T-cell activation and adherence," in cytokine release," and lateral movement of cells."
Prognosis of cancer patients greatly depends on the capacity of malignant cells to disseminate to distant sites in the body. The adhesive properties of tumor cells play a key role in the process of metastasis formation. CD44 molecule has an important role in hematogenous dissemination of nonHodgkin's 1ymph0rna.l~ Although they are often of highgrade malignancy, CD44-lymphomas are often local and have favorable prognosis."
A splice variant of CD44 (CD44v6) has been shown to confer metastatic potential to nonmetastazing rat pancreatic carcinoma cell lines.' It has recently been suggested that aggressive non-Hodgkin's lymphomas overexpress CD44 variants that contain the metastasis-associated exon ~6 . '~ Although it is evident that v6 containing forms of CD44 are also expressed in normal tissues, and malignant transformation of certain cell types results in decrease of CD44v6 expression,"~'* in a recent study, the presence of variant forms of CD44 in human was suggested to be a sign of malignant disease. ") At present, response assessment in lymphoma requires extensive examinations such as computed tomography (CT) scans of the mediastinum and the abdomen, and a bone marrow (BM) biopsy. Even after such examinations the presence of complete response may sometimes be difficult to ascertain without surgery because of the possibility of a nonmalignant residual tumor, and therefore, easier and less expensive methods to measure treatment response are needed. In this study, we wanted to analyze, whether measurement of serum CD44 has any value in this respect. A soluble form of the CD44 molecule has been detected in the serum'" and the synovial fluid,21 but its clinical and biologic significance is unsettled. In the present study, we investigated the occurrence of both the standard lymphocyte form of CD44 and the variant form CD44v6 in the sera of patients with lymphoma and healthy controls. Both forms of the molecule were found to be elevated in patients with lymphoma. Furthermore, serum CD44 levels diminished to the same level as we found in the controls if a clinically complete response was obtained with therapy.
C

MATERIALS AND METHODS
Patients. Serum CD44 and CD44v6 were measured in 34 consecutive patients with lymphoma treated in Turku University Central Hospital in 1992 to 1993, in 6 patients with Epstein-Barr virus (EBV) infection, and in 12 healthy controls. Twenty-six patients had nonHodgkin's lymphoma (16 had low grade and 10 high-grade lymphoma according to the modified Kiel classificationz2), and 8 had Hodgkin's disease. Twenty-four non-Hodgkin's lymphomas were of B-cell origin and 2 of T-cell origin. The hematopoietic origin of the tumors was confirmed in each case by routine histology and staining for the human leukocyte common antigen.
Twenty-one (62%) of the patients were male, and the median age was 52 years (range, 17 to 85 years). Clinical staging was done according to the Ann Arbor classification system." The clinical status, chest x-ray, CT scans of the mediastinum and the abdomen, and a BM biopsy were performed as staging examinations. TWO patients had stage I, 9 stage 11, 12 stage 111, and 11 stage IV disease. Seventeen patients had B symptoms (weight loss, unexplained fever, or night sweats). The controls were normal, healthy individuals, their median age was 34 years (range, 25 to 62 years), and seven of them were men.
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The patients were treated with an anthracycline containing combination chemotherapy except 4 patients. In addition, 10 patients received megavoltage radiotherapy. Abnormal staging examinations were usually repeated after the fourth and the sixth chemotherapy course to assess response to therapy.
A serum sample taken before treatment was available in 25 cases with lymphoma, and a sample taken at the time of lymphoma progression was available in l 1 cases. Serial serum samples, taken before treatment and thereafter before following chemotherapy courses (n = 6), were available in 13 cases. All CD44 and CD44v6 analyses were performed without knowledge of the clinical treatment response. Serum thymidine kinase was measured using the Prolifigen thymidine kinase radioenzyme assay (Santec Medical AB, Bromma, Sweden), and P2-microglobulin using Pharmacia P2-microglobulin radioimmunoassay (Pharmacia Diagnostics AB, Uppsala, Sweden).
All serum sampling procedures were approved by institutional human research comittees.
Antibodies against CD44 and CD44v6. Monoclonal antibody (MoAb) Hermes 3 has been shown to recognize an epitope from the constant part of the CD44 molecule. Production and specificity of Hermes 3 antibody have been described el~ewhere.'~ MoAb Var 3.1 recognizes exon v6 containing forms of variant CD44 (CD44v6).Ix As a negative control, an MoAb 3G6 against chicken T cells was used.
Dot-blor assay. Diluted serum samples were transferred onto a wet nitrocellulose membrane (Hybond-C Super; Amersham, Buckinghamshire, UK) using Dot Blot apparatus (The Convertible, Filtration Manifold System, GIBCO-BRL, Gaithersburg, MD). After the dot blotting the membrane was cut into strips. Nonspecific interactions were blocked by incubating the strips in phosphate-buffered saline (PBS) containing 10% dried nonfat milk powder and 0.3% Tween-20 for 60 minutes at room temperature. Then the strips were incubated with the first-stage antibody for 60 minutes at room temperature. MoAbs, Hermes 3, Var3.1, and 3G6 (10 pg/mL purified Ig or 1:lO dilution of serum-free supernatant) were diluted in PBS containing 0.3% Tween-20. Second-stage antibody was peroxidaseconjugated rabbit antimouse Ig (Dakopatt M S , Glostrup, Denmark), and incubation time was 60 minutes at room temperature. Between incubations, the strips were extensively washed with PBS containing 0.3% Tween 20. Immunodetection was performed using an enhanced chemiluminescence system (ECL; Western blotting detection system, Amersham). Light emission was detected with Hyperfilm-ECL (Amersham). The intensity of the dots was measured by using the Microcomputer Imaging Device (MCID; Imaging Research Inc, Ontario, Canada). Four of the sample series and eight single samples were analyzed twice to control the reproducibility of the dot blot method. One sample was included as an internal reference sample in every assay, and for CD44v6 measurements, the value of this sample was assigned the value of 1. All test samples were standardized using this reference sample, and the values of serum CD44v6 are presented as units. The serum CD44 concentrations (ng/mL) of samples were calculated using a standard curve of serial dilutions of known amounts of purified CD44 protein.
Molecular-weight analyses of soluble CD44. To determine the size of soluble forms of CD44 in the serum, CD44 antigens were isolated using immunoaffinity chromatography, separated by sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and detected by immunoblotting. Diluted serum samples (200 pL serum + 800 pL PBS) were precleared by subjecting them to two rounds of absorption with Sepharose 4B beads (Pharmacia, Uppsala, Sweden) derivatized with normal mouse serum and with an irrelevant MoAb ( 3 mg Ig/l mL cyanogen bromide-activated Sepharose 4B beads, 100 pL beadslsample). Thereafter, CD44 was specifically precipitated from the precleared serum samples with Sepharose 4B beads coupled to Hermes-3 antibody. After overnight incubation, the beads were washed three times with a detergentcontaining buffer (1% NonIdent P-40 in 0.15 mol& NaCl, 0.01 mol/ L TRIS, 1.5 mmol/L MgCIZ pH 7.2) and the antigen was eluted with 50 mmoVL triethylamine. The eluate was evaporated in a vacuum microfuge, and the antigen was resuspended in Laemmli's sample buffer (without reducing agents). CD44 antigens were resolved according to their molecular weights by an SDS-PAGE (5% to 12.5% gradient gels), and then electrophoretically transferred onto a nitrocellulose membrane (Hybond-C Super, Amersham) using TransBlott SD Semidry apparatus (Bio-Rad Laboratories, Hercules, CA). After blotting, the membrane was cut into strips that were stained with Hermes-3 and 3G6 using ECL detection system for Western blotting as described above.
Statistical analysis. Statistical analyses were done with the BMDP computer program (BMDP Statistical Software, Department of Biomathematics, University of California, Los Angeles, CA). Comparison of nonnormal distributions was done using KruskalWallis analysis of variance or Mann-Whitney's U-test. Serum marker values measured before and after treatment were compared with Wilcoxon signed rank test. Correlation between CD44 and CD44v6 at the time of the diagnosis was performed by calculating the Spearman rank correlation coefficient. Variance in CD44 and CD44v6 levels in repeated measurements among the controls was analyzed with analysis of variance. All P values are two tailed.
RESULTS
Serum CD44 levels measured at diagnosis are shown in Table 1 . In healthy controls, CD44 levels were low and constant in three separate samples ( P = .56) taken at least 1 week apart. Patients with lymphoma (n = 25) had almost 20-fold higher serum CD44 levels at the time of diagnosis than the controls ( P < .0001). Serum CD44 levels of six patients with EBV infection were low (median 30 ng/mL, range 10 to 130 ng/mL), and they did not statistically differ from CD44 levels of healthy controls ( P = .35). Serum CD44v6 levels were slightly higher in patients with lymphoma at the time of diagnosis than in controls ( P = .046).
In patients who had achieved a complete response by clinical, radiologic, and histologic evidence, (n = 11) the measured CD44 levels were not different from those of the controls ( P = S 3 ) . In contrast, significantly elevated values were found in sera of the patients who had progressive disease (n = 11, P = .0001, Fig 1) . Similarly, patients in complete remission had similar serum CD44v6 concentrations as the controls ( P = .23).
Serial measurements of CD44 and variant CD44 were performed in 4 patients with Hodgkin's disease and 9 with non-Hodgkin's lymphoma (Fig 2) . Serum CD44 levels changed in parallel with the clinical course, as can be seen from two typical examples shown in Fig 3. Patients who achieved a complete response and who had serial measurements performed (n = 10) had lower serum CD44 and CD44v6 levels at complete response than before treatment (the median CD44 decreased from 240 ng/mL to 10 ng/mL, P = .002; and the median CD44v6 from 2.6 U to 1.2 U, P = .006). Serum ,8-2-microglobulin and thymidine kinase levels were serially measured in 6 of these 10 patients, but no consistent association with the treatment response was found with either marker (Fig 3) .
The serum level of CD44 or CD44v6 measured at the time of the diagnosis was not associated with the median age at diagnosis, gender, Ann Arbor clinical stage, or serum lactate dehydrogenase concentration in the entire series (n = 25) or among patients with non-Hodgkin's (n = 19) or Hodgkin's lymphoma (n = 6). Similarly, there was no significant difference in serum CD44 or CD44v6 concentrations between patients with low (n = 11) and high-grade (n = 8) non-Hodgkin's lymphoma ( P = 0.64 and P = 0.68 respectively), and no significant association between the CD44 and CD44v6 concentrations measured at diagnosis was found. However, lymphoma patients with higher than the median (1 1.8 U L ) thymidine kinase concentration at diagnosis (measured in 9 cases) had also a higher CD44 concentration at diagnosis ( P = .OS). Lymphoma patients with B symptoms tended to have larger serum CD44v6 concentrations ( P = .07) than those without these symptoms, and this association was significant ( P = .04) among patients with non-Hodgkin's lymphoma (n = 19). No association between the presence of B symptoms and the CD44 level was found.
The molecular weight of serum CD44 molecule was measured to be 70 to 80 k D , and its size did not differ between lymphoma patients and the controls. Bands of larger size, at least partially consisting of the variant forms of CD44, were also seen (Fig 4) .
DISCUSSION
Serum CD44 and CD44v6 were detected in sera of both healthy controls and patients with untreated lymphoma. Serum CD44 was isolated from the normal human plasma in 1989,'" but its origin and clinical importance are still unsettled. CD44 is expressed by several hematopoietic and nonhematopoietic cells, and it can be detected in about 90% of non-Hodgkin's lymphomas from paraffin-embedded tissue sections by immunohistochemistry." It has been suggested that shedding is an important regulatory mechanism to control cell surface expression of CD44 in leukocyte^.'^ We found the molecular weight of serum CD44 to be 70 to 80 kD both in lymphoma patients and in controls. This size is within the same range as has been reported to be the shed form of CD44 from lymphocytes. Therefore, serum CD44 could originate from stimulated leukocytes." Whether the serum CD44 is shed from lymphoma cells or whether it is shed as a response of normal cells to control lymphoma growth is not currently known. However, the disappearance of serum CD44 in parallel with lymphoma tissue suggests that some of serum CD44 may have its origin in lymphoma deposits in patients with lymphoma. Although there was no statistical difference in serum CD44 level between low-and high-grade lymphomas, the positive association between serum CD44 and serum thymidine kinase level suggests that the release of CD44 from lymphoma tissue may be associated with cell proliferation. Because CD44v6 was present in sera of all 12 healthy controls, its presence in the serum is not a sign of malignancy as has been suggested earlier." Patients with untreated lymphoma had higher serum CD44v6 levels than the controls, and serum CD44v6 levels became lower in serial measurements in patients who achieved a complete response. However, the changes in CD44v6 levels were not as significant as those in serum CD44 levels. Therefore, larger variant forms of CD44 are likely to be more important as serum markers in epithelial malignancies than in lymphoma. Larger forms of CD44 may consist also of other splice variants than exon v6 containing CD44. However, the differences between concentrations of soluble CD44 are mainly caused by the variations in the level of the 70-to 80-kD form of CD44 as can be seen in serum CD44v6 concentrations, which might suggest that cytokines have a role in CD44v6 shedding.
Lactate dehydrogenase,'" thymidine kinase," and P-2-microglobulin'x have been used as serum markers of lymphoma. If measured before the beginning of treatment, they all have prognostic value in lymphoma, and lactate dehydrogenase and thymidine kinase levels also correlate with the tumor mass. In addition, high levels of thymidine kinase are associated with a rapid proliferation rate of lymphoma. However, all these markers have low specificity and sensitivity, and cancer therapy may greatly affect their serum values making them unreliable in response assessment. In our series, high serum thymidine kinase and P-2-microglobulin levels were measured in patients with complete response, which was not found to be the case with CD44.
Banal viral infections of the upper respiratory tract did not influence the serum CD44 levels in lymphoma patients or in healthy controls. Also, in all six patients with EBV infection, serum CD44 levels remained low despite the presence of a lymphoproliferative disease. This was surprising because the differential diagnosis between aggressive monoRlSTAMAKl ET AL nucleosis and lymphoma may sometimes be problematic even histologically. Neither did septic, neutropenic infections during chemotherapy courses change serum CD44 levels (n = 4). On the other hand, severe and active rheumatoid arthritis is sometimes associated with increased levels of serum CD44 (manuscript in preparation). Therefore, lymphoma patients with such a disease form a small group of patients whose elevated serum CD44 values should be judged with caution.
In conclusion, serum CD44 levels seem to correlate well with the clinical behavior of lymphoma, and therefore, may be useful as a marker of treatment response. Serum CD44 level may also give further information for diagnostic purposes. Whether serum CD44 can be used to diagnose lymphoma recurrence before it becomes clinically apparent remains to be determined. However, this type of serum marker for malignant lymphoma might find applications, eg, in clinical trials, where the number of chemotherapy cycles given could be adjusted by the disappearance of CD44 from the patient's serum to find the optimal treatment duration.
